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Abstract
The six transmembrane protein of prostate 2 (STAMP2) is an andro-
gen-regulated gene whose mRNA expression is increased in pros-
tate cancer (PCa). Here, we show that STAMP2 protein expression
is increased in human PCa compared with benign prostate that is
also correlated with tumor grade and treatment response. We also
show that STAMP2 significantly increased reactive oxygen species
(ROS) in PCa cells through its iron reductase activity which also
depleted NADPH levels. Knockdown of STAMP2 expression in PCa
cells inhibited proliferation, colony formation, and anchorage-
independent growth, and significantly increased apoptosis.
Furthermore, STAMP2 effects were, at least in part, mediated by
activating transcription factor 4 (ATF4), whose expression is regu-
lated by ROS. Consistent with in vitro findings, silencing STAMP2
significantly inhibited PCa xenograft growth in mice. Finally,
therapeutic silencing of STAMP2 by systemically administered
nanoliposomal siRNA profoundly inhibited tumor growth in two
established preclinical PCa models in mice. These data suggest that
STAMP2 is required for PCa progression and thus may serve as a
novel therapeutic target.
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Introduction
Prostate cancer (PCa) is the most frequently diagnosed non-skin
cancer and second leading cause of cancer deaths among men in
Europe and the USA (Siegel et al, 2012). PCa growth is initially
dependent on circulating androgens and hormonal therapies aimed
at androgen deprivation result in regression. However, in the major-
ity of cases, the disease recurs as a castration-resistant PCa (CRPC)
that leads to death regardless of available treatment options. Despite
recent advances, the molecular mechanisms involved in PCa devel-
opment and progression to CRPC are still not well understood
(Arnold & Isaacs, 2002; Shen & Abate-Shen, 2010; Dayyani et al,
2011; Yap et al, 2011). This information is necessary for biomarker
discovery for disease stratification as well as identifying therapeutic
targets for PCa (Prensner et al, 2012).
Previous studies have shown that androgen signaling, mediated
by the androgen receptor (AR), has a role in all phases of PCa,
including CRPC (Arnold & Isaacs, 2002; Shen & Abate-Shen, 2010;
Dayyani et al, 2011; Yap et al, 2011; Bluemn & Nelson, 2012). AR
activation regulates a large cluster of genes involved in multiple
aspects of cellular function. Genome-wide explorations have
revealed that several hundred genes are primary targets of AR
in PCa cells (Velasco et al, 2004; Lai et al, 2010). In addition,
deregulated androgen signaling increases reactive oxygen species
(ROS) in PCa (Ripple et al, 1997; Sun et al, 2001; Tam et al, 2003;
Frohlich et al, 2008; Basu et al, 2009), consistent with other work
which suggests that PCa development is associated with oxidative
stress (for a review, see Paschos et al, 2013). However, the precise
molecular events that cause changes in the generation of ROS in
PCa are currently not known.
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We have previously identified STAMP2 as an androgen-regulated
gene (Korkmaz et al, 2005). STAMP2 mRNA is expressed in the
prostate epithelium and is significantly overexpressed in PCa
compared with benign prostate; consistently, ectopic expression of
STAMP2 promoted PCa cell proliferation (Korkmaz et al, 2005).
Although these observations suggested that STAMP2 may have a
role in PCa biology, it is not clear as to how STAMP2 modulates cell
growth in PCa cells and whether it can serve as a therapeutic target.
Interestingly, STAMP2 has also been linked to inflammation and
insulin action in adipocytes and macrophages and thus has been
implicated in metabolic disease and atherosclerosis (Wellen et al,
2007; ten Freyhaus et al, 2012).
Here, we show that STAMP2 is a critical survival factor for PCa
cells in vitro and in vivo and that it activates oxidative stress-
induced ATF4 signaling through ROS generated by its iron reductase
activity. Consistently, therapeutic silencing of STAMP2 in two estab-
lished preclinical PCa models in mice by nanoliposomal siRNA
delivery results in profound tumor regression.
Results
STAMP2 expression is up-regulated in human PCa specimens
We have previously shown that STAMP2 mRNA expression is
increased in PCa compared with benign prostate (Korkmaz et al,
2005). To evaluate the validity of this finding at the protein level, we
assessed STAMP2 expression by immunohistochemistry on a tissue
microarray (TMA) that contained benign prostate tissue (n = 27)
and malignant prostate tissue with Gleason score < 7 (n = 35) or ≥ 7
(n = 149). Benign prostate tissue showed low STAMP2 staining,
while STAMP2 expression was significantly increased in PCa
compared to normal cells (Fig 1A). In addition, STAMP2 cytosolic
staining correlated with the tumor grade (Gleason score) (Fig 1B).
Of interest, STAMP2 staining was restricted to the cytosol in low-
grade prostate tumors, whereas its cell membrane localization signif-
icantly increased in high-grade tumors (Fig 1C and D).
STAMP2 has a critical role in PCa growth both in vitro and in vivo
We have previously found through ectopic expression in DU145 PCa
cells that STAMP2 may have a role in cell proliferation (Korkmaz
et al, 2005). To evaluate this further, we assessed whether reduction
in endogenous STAMP2 expression influences growth characteris-
tics of PCa cells. STAMP2-specific siRNAs significantly decreased
STAMP2 expression compared with control siRNA in LNCaP cells
(Fig 2A and Supplementary Fig S1A). Knockdown of STAMP2
significantly inhibited androgen-dependent growth of LNCaP cells
measured by cell number and colony formation capacity (Fig 2B
and C). Consistently, LNCaP cells stably expressing STAMP2 shRNA
displayed reduced growth rates both in vitro (Fig 2D–G) and in vivo
(Fig 2H).
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Figure 1. STAMP2 expression during PCa progression.
A Immunohistochemistry was used to assess STAMP2 expression in normal and malignant human prostate specimens. Tissue microarrays (TMAs) with normal
prostate (n = 27) and early-stage (Gleason grade < 7) (n = 35) or late-stage prostate tumors (Gleason grade ≥ 7) (n = 149) were subjected to
immunohistochemistry as described in Materials and Methods. Representative images are shown.
B Quantification of cytosolic STAMP2 staining in TMAs is shown in (A). One-way analysis of variance (ANOVA) with a post hoc test, *P < 0.0001. Error bars
indicate SEM.
C, D The details of cytosolic (C) and membrane (D) STAMP2 staining in the TMAs described in (A).
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To generalize these observations, we validated the contribution
of STAMP2 to cell growth in an additional androgen-responsive PCa
cell line, VCaP. Similarly, in LNCaP cells, knockdown of STAMP2
(Supplementary Fig S1B) significantly inhibited VCaP cell growth
(Fig 2I and J). Collectively, these data show that STAMP2 has an
important role in PCa cell growth in vitro and in vivo.
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Figure 2. STAMP2 promotes PCa growth in vitro and in vivo.
A LNCaP cells were transfected with either control siRNA or two independent STAMP2 siRNAs, and membrane fractions of the cells were prepared followed by Western
blotting analysis. STAMP1 is used as a loading control.
B LNCaP cells were cultured in RPMI 1640 medium containing 10% CT-FBS and treated with or without 1 nM R1881 for 24 h before being transfected with the
indicated siRNAs. The cells were then cultured for the indicated times, and cell growth was measured by Cell Counting Kit-8. n = 3, *P < 0.0001. Error bars
indicate SD.
C LNCaP cells were cultured and transfected with the indicated siRNAs as described in (B). After transfection, the cells were cultured for 10 days. The colonies formed
were stained and photographed.
D LNCaP cells stably expressing shRNA against STAMP2 or control shRNA were treated with or without 1 nM R1881. The cells were then collected, and membrane
fractions were prepared followed by Western blot analysis.
E LNCaP cells stably expressing shRNA against STAMP2 or control shRNA were cultured for the indicated times, and the cell numbers were determined using a
hemocytometer. n = 3, *P = 0.047; **P = 0.0046. Error bars indicate SD.
F LNCaP cells stably expressing shRNA against STAMP2 or control shRNA were cultured in soft agar for 2 weeks as described in Materials and Methods. The plates were
then stained and photographed.
G Quantification of data from (F). n = 3, *P = 0.022. Error bars indicate SD.
H LNCaP cells stably expressing shRNA against STAMP2 or control shRNA were subcutaneously implanted into male SCID mice. Tumor size was measured after 8 weeks.
n = 9, *P = 0.037. Error bars indicate SEM.
I VCaP cells were transfected with the indicated siRNA as described in (B). After transfection, VCaP cells were cultured for 2 weeks. The colonies formed were stained
and photographed.
J Quantification of the data from (I). n = 3, *P < 0.0001. Error bars indicate SD.
Data information: In (B, E, G, H, and J), Student’s t-test was performed to analyze the statistical significance.
Source data are available online for this figure.
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STAMP2 affects cell cycle progression of PCa cells and their
sensitivity to apoptosis-inducing agents
We next evaluated whether the growth stimulatory effects of
STAMP2 could be mediated by impacting the cell cycle. As shown
in Fig 3A and B, upon STAMP2 knockdown, there was a significant
increase in the percentage of cells in G0/G1, indicating that loss of
STAMP2 led to partial cell cycle arrest. Consistently, expression
of CDK inhibitor p21CIP1 was up-regulated, while the proliferation
marker proliferating cell nuclear antigen (PCNA) was down-
regulated by STAMP2 knockdown (Fig 3C).
In addition to its effects on proliferation, we investigated the
possible involvement of STAMP2 in regulating apoptosis in PCa
cells. No significant changes in basal levels of apoptosis were
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Figure 3. STAMP2 affects cell cycle progression and increases sensitivity of PCa cells to apoptosis-inducing drugs.
A LNCaP cells were transfected with either control or STAMP2-specific siRNA. Two days after transfection, cells were subjected to cell cycle analysis as described in
Materials and Methods. Representative histograms showing PI-stained cells are shown.
B The proportion of cells in each stage of the cell cycle from the experiment in (A) is presented. Student’s t-test was performed to analyze the statistical significance,
n = 3. *P = 0.0002; **P = 0.0056; ***P = 0.0099. Error bars indicate SD.
C Two days after transfection with the indicated siRNAs, LNCaP cells were harvested and cell lysates were prepared and subjected to Western blot analysis with the
indicated antisera. Representative blots of three independent experiments are shown.
D LNCaP cells were transfected with either control or STAMP2-specific siRNA. Three days after transfection, cells were treated with either 50 ng/ml TRAIL or 20 lmol/l
LY294002 (LY) for 24 h, or both agents for 6 h, and then subjected to TUNEL/FACS analysis. Representative histograms of TUNEL-stained cells are shown. FL1-H refers
to the gating of the cells for the TUNEL staining with fluorescence measurement.
E The extent of apoptosis from the experiment in (D) is presented. Student’s t-test was performed to analyze the statistical significance, n = 3. *P = 0.027; **P = 0.0058;
***P = 0.0016. Error bars indicate SD.
F LNCaP cells were transfected with either control or two independent STAMP2-specific siRNAs, ST2-1 and ST2-2. Three days after transfection, cells were treated in the
same way as in (D). Whole-cell lysates were prepared and subjected to Western blot analysis with the indicated antisera.
G LNCaP cells stably expressing either control or STAMP2 vector were treated in the same way as in (D). Cell lysates were prepared and subjected to Western blot
analysis with the indicated antibodies.
Source data are available online for this figure.
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detected upon STAMP2 knockdown (data not shown). We then
determined whether STAMP2 knockdown influences the sensitivity
of LNCaP cells to apoptosis inducers, tumor necrosis factor (TNF)-
related apoptosis-inducing ligand (TRAIL) (Yu et al, 2000) and PI3K
inhibitor (LY294002) (Chen et al, 2001). LNCaP cells were transfected
with either control siRNA or two independent siRNAs against
STAMP2, and the cells were then treated with either TRAIL or
LY294002 alone, or in combination, and the extent of apoptosis was
determined. STAMP2 knockdown significantly increased cell death
induced by TRAIL or LY294002 alone, as well as TRAIL plus
LY294002 (Fig 3D and E). Consistent with a role in regulating apopto-
sis, STAMP2 knockdown increased cleavage of PARP and caspase-3
in response to TRAIL, LY294002, or their combination (Fig 3F,
Supplementary Fig S1C and D). Conversely, ectopic expression of
STAMP2 attenuated caspase-3 and PARP cleavage induced by
LY294002 compared to control (Fig 3G). These data show that
STAMP2 inhibits pro-apoptotic factor signaling in PCa cells and
thereby contributes to cell survival.
STAMP2 is associated with the development of hormone
refractory PCa
Because STAMP2 is an androgen-regulated gene in PCa cells (Korkmaz
et al, 2005) and contributes to their androgen-dependent growth
(Fig 2), we set out to examine STAMP2 expression in PCa patients
treated with neoadjuvant hormone therapy. STAMP2 levels were
significantly reduced following neoadjuvant hormone therapy and
remained low in patients responding to therapy (Fig 4A and B).
A B
C D
Figure 4. STAMP2 expression is associated with development of castration resistance of PCa.
A STAMP2 expression was determined by IHC of a neoadjuvant hormone therapy (NHT) TMA containing samples from hormone naïve (untreated) (n = 28), NHT
1–6 months (n = 31), NHT 7–12 months (n = 41), and patients with PSA recurrence (n = 21) as indicated. Representative images are presented.
B Quantitative presentation of the data from (A). Unt, untreated; Recur, PSA recurrence. The Kruskal–Wallis test was used for significance analysis. *P = 0.0499. Error
bars indicate SEM.
C Boxplots of STAMP2 expression levels in normal prostate tissue, primary prostate cancer, and metastatic CRPC were analyzed in two independent GEO datasets (GSE6919
and GSE35988). The values of individual samples are presented as dots. Thick horizontal lines represent the median, with the box representing the upper and lower
quartile. The whiskers represent the 5th and 95th percentiles. The statistical significance, indicated in the tables at the bottom, was determined by Student’s t-test.
D CWR22 xenografts were grown in nude mice, and tumors were collected at different times after castration. mRNA was extracted from the tumors and used for qPCR
analysis of STAMP2 expression. The results are presented as boxplots. Thick horizontal lines represent the median, with the box representing the upper and lower
quartile. The whiskers represent the 5th and 95th percentiles, and the outlier is presented as an open circle. The statistical significance was determined by one-way
ANOVA with a post hoc test. n = 3 in group week 0, 1, 2, and 4; n = 5 in refractory group. *P = 0.011; **P = 0.049. Error bars indicate SEM.
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Interestingly, upon PSA recurrence, STAMP2 levels were again
increased (Fig 4A and B). As PSA recurrence is associated with the
development of CRPC, we next examined STAMP2 expression in
PCa cohorts that included matched primary PCa and CRPC tissues.
As shown in Fig 4C, in two independent cohorts, there was an
increase in STAMP2 expression in primary PCa tissues, compared to
normal prostate. Furthermore, STAMP2 expression was significantly
higher in CRPC compared to primary PCa. Consistently, STAMP2
expression was significantly reduced shortly after castration in
human PCa xenograft CWR22 grown in immunodeficient mice and
then increased in the refractory derivatives (Fig 4D). Collectively,
these data suggest that STAMP2 expression is associated with CRPC
development.
STAMP2 is involved in androgen-insensitive PCa growth
As STAMP2 expression is significantly increased in CRPC, we next
assessed the possible function of STAMP2 in 22Rv1 cells, a CRPC
model cell line derived from the refractory CWR22R xenografts that
grow in an androgen-independent manner in vitro and in vivo
(Sramkoski et al, 1999). STAMP2 knockdown significantly reduced
22Rv1 growth in the presence or absence of androgen (Fig 5A and B).
To assess the validity of these findings in vivo, we generated cell
lines that stably express either scrambled shRNA or shRNA targeting
STAMP2. Consistent with the data obtained with siRNA, STAMP2
shRNA expressing cells grew significantly less colonies compared
with cells expressing scrambled shRNA (Supplementary Fig S2A
and B). Furthermore, when grown as xenografts in nude mice,
STAMP2 knockdown cells developed significantly smaller tumors
compared with control cells (Fig 5C and D). These data are consis-
tent with those from above and suggest that STAMP2 is associated
with CRPC.
STAMP2 is necessary for ATF4 signaling
To probe the possible signaling pathways which STAMP2 may
affect, we performed global gene expression profiling in LNCaP cells
upon STAMP2 knockdown compared with control cells. Global gene
expression data revealed that activating transcription factor 4
(ATF4) expression and that of its target genes (e.g. ASNS and
SLC7A11) were significantly reduced upon STAMP2 knockdown
(Supplementary Fig S3A). This was validated by quantitative PCR
and Western blot analysis (Fig 6A and B). Similar effects of STAMP2
loss on ATF4 expression were observed in LNCaP cells and 22Rv1
cells stably expressing STAMP2 shRNA (Fig 6C and D), while
ectopic expression of STAMP2 in LNCaP cells induced ATF4 expres-
sion (Supplementary Fig S3B). Consistently, in the xenograft tumors
formed by 22Rv1 cells with STAMP2 knockdown (Fig 5C), expres-
sions of ATF4 and its target gene ASNS were significantly reduced
(Fig 6E). In addition, ATF4 expression was significantly increased in
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Figure 5. STAMP2 loss inhibits androgen-insensitive PCa cell growth in vitro and in vivo.
A 22Rv1 cells were cultured in RPMI 1640 medium containing 10% CT-FBS and treated with or without 1 nM R1881 for 24 h and were then transfected with the
indicated siRNAs. The cells were then cultured for 10 days. The colonies formed were stained and photographed.
B Quantification of data from (A). Student’s t-test was performed to analyze the statistical significance, n = 3. *P = 0.0003; **P < 0.0001. Error bars indicate SD.
C 22Rv1 cells from Supplementary Fig S2 were subcutaneously implanted into both flanks of male nude mice (six mice per group). Tumor size was measured at the
indicated time points. Student’s t-test was performed to analyze the statistical significance, n = 10. *P = 0.037; **P = 0.039. Error bars indicate SEM.
D Representative tumors from (C) right after resection at the final time point are shown.
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relapsed CWR22 xenograft tumors, in parallel with a significant
increase in STAMP2 expression (Fig 6F).
To assess the relevance of these findings to human PCa, we next
examined possible correlation of STAMP2 and ATF4 expression in a
PCa gene expression profile dataset (Taylor et al, 2010). Hierarchi-
cal clustering analysis was performed, and subgroups showing
higher or lower STAMP2 expression were used for further analysis.
As shown in Fig 6G, there was a significant positive correlation
between STAMP2 and ATF4 expression (R = 0.4015, P < 0.00001),
as well as established ATF4 target genes ASNS and SLC7A11. Similar
results were obtained in two independent cohorts (Supplementary
Fig S3C). Taken together, these data establish that STAMP2 is
involved in regulating ATF4 expression.
STAMP2 increases PCa cell growth by regulating ATF4 expression
ATF4 is an ER stress-, metabolic stress-, and oxidative stress-inducible
transcription factor which has key roles in antistress responses
(Ye & Koumenis, 2009; Lewerenz & Maher, 2011). Given the above
data, we investigated whether ATF4 is involved in STAMP2-medi-
ated proliferative effects on PCa cells. Upon ATF4 knockdown in
LNCaP cells (Fig 7A), cell growth was significantly decreased
(Fig 7B and C), indicating that similar to STAMP2, ATF4 is involved
in PCa cell growth. We then investigated whether re-expression of
ATF4 could reverse cell growth inhibition mediated by STAMP2
knockdown. To that end, LNCaP cells stably expressing an empty
vector or a vector expressing ATF4 were established by lentivirus
delivery (Fig 7D). These cells were then transfected with either
control or STAMP2 siRNA and then allowed to grow to form colo-
nies. As shown in Fig 7E and F, STAMP2 siRNA-mediated decrease
in colony formation was significantly reversed upon ectopic ATF4
expression. This suggests that STAMP2 effects in PCa cells are medi-
ated, at least in part, through ATF4. A target gene of ATF4, ASNS,
was recently shown to mediate the prosurvival effect of ATF4 in
solid tumor cells (Ye & Koumenis, 2009). To evaluate whether this
is the case in PCa, we knocked down ASNS in LNCaP cells by siRNA
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Figure 6. STAMP2 affects ATF4 expression in PCa cells.
A LNCaP cells were transfected with either control or STAMP2-specific siRNA in the presence of 108 M R1881. RNA was isolated, and qPCR was used to determine
ATF4 mRNA levels. Student’s t-test was used to analyze the statistical significance, n = 3. *P = 0.002. Error bars indicate SD.
B Cell lysates from (A) were subjected to Western blot analysis.
C, D ATF4 expression in LNCaP (C) and 22Rv1 (D) cells stably expressing control shRNA or shRNA against STAMP2 was analyzed by Western blot analysis.
E ATF4 expression in xenografted tumors of 22Rv1 cells stably expressing control shRNA or shRNA against STAMP2 was analyzed by qPCR. Student’s t-test was used
to analyze the statistical significance, n = 4. *P = 0.022; **P = 0.015; ***P = 0.044. Error bars indicate SEM.
F CWR22 xenografts were grown in nude mice, and tumors were collected at different times after castration. The association between ATF4 and STAMP2 in the
tumor samples was determined by Western blot analysis.
G The MSKCC Prostate Oncogenome cDNA microarray dataset was obtained from the cBio Cancer Genomics Portal. Analysis was performed as described in Materials
and Methods. The expression levels of STAMP2 and ATF4, as well as two ATF4 target genes (ASNS and SLC7A11), are presented.
Source data are available online for this figure.
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which resulted in a significant reduction in cell growth (Fig 7G
and H). These data further confirmed the prosurvival role of ATF4
signaling in PCa cells.
STAMP2 has ferrireductase activity and increases ROS levels
Previous studies have shown that ATF4 expression is induced by
oxidative stress (Cullinan & Diehl, 2006). Since STAMP2 is linked to
ATF4 expression, oxidative stress may be affected by intracellular
iron levels (Knobel et al, 2006). Furthermore, mouse Stamp2 has
iron reductase activity in 293T cells (Ohgami et al, 2006). We thus
hypothesized that STAMP2 expression may contribute to intracellu-
lar ROS generation and thus ATF4 expression. We first assessed the
iron reductase activity of human STAMP proteins ectopically
expressed in 293T cells (Fig 8A). In contrast to the mouse STAMPs,
only STAMP2 displayed iron reductase activity in the human family
(Fig 8B). Mutagenesis of the putative FAD (dGSR) or heme-binding
sites (H304L or H397L) abolished STAMP2 iron reductase activity
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Figure 7. STAMP2 affects PCa cell growth through regulating ATF4 expression.
A LNCaP cells were transfected with either control or ATF4 siRNA. Two days after transfection, cells were harvested and whole-cell lysates were made and used in
Western blot analysis.
B LNCaP cells were transfected with either control or ATF4 siRNA and were cultured for 2 weeks. The colonies formed were stained and photographed.
C The area covered by the colonies on each plate in (B) was quantified and represented as percentage of the total area of the plate. *P = 0.0023.
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the indicated antisera.
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G LNCaP cells were transfected with either control (Ctrl) or ASNS siRNA. The cells were then cultured for 2 weeks. The colonies formed were stained and photographed.
Knockdown of ASNS was confirmed by Western blot analysis shown at the top.
H Quantification of the data shown in (G). *P = 0.0087.
Data information: In (C, F, and H), Student’s t-test was used to analyze the statistical significance, n = 3. Error bars indicate SD.
Source data are available online for this figure.
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(Fig 8C and D) consistent with findings on mouse Stamp2 (Ohgami
et al, 2005, 2006). To follow up on these findings, we generated a
293T cell line with doxycycline (Dox)-inducible STAMP2 expression
(Fig 8E) in which iron reductase activity was induced in a Dox-
dependent manner (Fig 8F). Moreover, the oxidoreductase inhibitor
diphenyleneiodonium sulfate (DPI), which inhibits flavoproteins,
suppressed STAMP2 activity in a dose-dependent manner (Fig 8G).
These data show that human STAMP2 has ferrireductase activity.
We next assessed whether the iron reductase activity of STAMP2
is associated with oxidative stress. Ectopic STAMP2 expression in
293T cells significantly enhanced ROS levels (Fig 8H, Supplemen-
tary Fig S4). Furthermore, the elevation in ROS upon STAMP2
expression was abolished by DPI (Fig 8I). Although DPI is a widely
used inhibitor of ROS generating oxidoreductases, under some
conditions, it has been shown to have inhibitory effects on other
flavoproteins that can affect ROS levels in the cell (Riganti et al,
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Figure 8. ROS generation by STAMP2 depends on its ferrireductase activity.
A 293T cells were transfected with plasmids expressing either an empty vector (Vec) or vectors expressing HA-tagged STEAP, STAMP1 (ST1), STAMP2 (ST2), or STAMP3
(ST3). Whole-cell extracts were prepared and subjected to Western blot analysis using anti-HA antibody or GAPDH as a loading control.
B Relative ferrireductase activities were measured in the cells expressing the different constructs used in (A) as described in Materials and Methods. *P < 0.0001.
C 293T cells were transfected with different plasmids expressing either an empty vector (Vec) or vectors expressing His-tagged wild-type STAMP2 (WT) or three STAMP2
mutants (dGSR, H304L, or H397L) as indicated. Whole-cell extracts were prepared and used in Western blot analysis with anti-His antibody or GAPDH antibody as a
loading control.
D Relative ferrireductase activities were measured in the cells from (C) as described in Materials and Methods. *P = 0.0003.
E 293T cell line with Dox-inducible STAMP2 expression or vector control was generated. Western blot analysis confirmed STAMP2 expression in a Dox-inducible manner.
F The cells from (E) were either left untreated or treated with increasing amounts of Dox, and ferrireductase activity was determined. *P < 0.0001.
G The cells with Dox-inducible STAMP2 expression from (E) were either left untreated or treated with Dox for 48 h. Prior to ferrireductase activity measurement, the
cells were treated with or without DPI as indicated for 1 h. *P < 0.0001; **P = 0.0012; ***P = 0.048.
H The cells from (E) were treated with 100 ng/ml Dox for 2 days. Oxidative stress was then measured by NBT staining, and the stained cells were photographed. There
were equal numbers of cells on the plates for /+ Dox as shown in Supplementary Fig S4.
I The cells with Dox-inducible STAMP2 expression from (E) were either left untreated or treated with Dox for 48 h. Then, the cells were treated with or without 10 lM
DPI before being subjected to NBT staining. *P < 0.0001.
Data information: In (B, D, F, G, and I), Student’s t-test was used to analyze the statistical significance, n = 3. Error bars indicate SD.
Source data are available online for this figure.
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2004). Thus, to further confirm the dependence of STAMP2
ferrireductase activity for ROS production, we used the dGSR
mutant of STAMP2 and compared its ability to generate ROS with that
of wild-type STAMP2. As shown in Fig 9C, inactivation of STAMP2
ferrireductase function completely abolished superoxide production.
To further evaluate the involvement of STAMP2 in ROS generation,
we used the antioxidant N-acetyl cysteine (NAC) which effectively
inhibited STAMP2-induced NBT reduction (Supplementary Fig S5).
These data show that STAMP2-mediated increase in oxidative stress
requires its ferrireductase activity.
To determine whether oxidative stress also induces ATF4 expres-
sion in PCa cells, we used menadione, an agent that increases intra-
cellular ROS levels (Cafe et al, 1995). As shown in Supplementary
Fig S6A and B, ATF4 mRNA and protein levels were significantly
increased in LNCaP cells in response to menadione, indicating that
oxidative stress regulates ATF4 expression in PCa cells. We then
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Figure 9. STAMP2 increases intracellular ROS by decreasing intracellular NADPH levels.
A LNCaP cells stably expressing an empty vector (LN-Vec) or a vector expressing STAMP2 (LN-ST2) were established by lentivirus delivery. Cell lysates were prepared and
subjected to Western blot analysis with the indicated antisera.
B Relative ferrireductase activities were measured in the cells described in (A). *P = 0.0003.
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E LNCaP cells stably expressing an empty vector (Vec), a vector expressing wild-type STAMP2 (WT), or a STAMP2 mutant (dGSR) were cultured, and the NADPH/NADP+
ratio was determined as described in Materials and Methods. *P = 0.015.
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Data information: Student’s t-test was used to analyze the statistical significance, n = 3. Error bars indicate SD.
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determined whether STAMP2-induced ATF4 expression in PCa cells
could be inhibited by an antioxidant. To that end, LNCaP cells
ectopically expressing STAMP2 or vector control were either left
untreated or treated with N-acetyl cysteine (NAC) and ATF4 protein
levels were determined by Western blot analysis. As shown in
Supplementary Fig S6C, NAC treatment completely inhibited
STAMP2-induced ATF4 expression. Consistently, inducible expres-
sion of STAMP2 in 22RV1 cells increased ATF4 expression which
was blocked in response to NAC treatment (Supplementary Fig
S6D). In addition, the ferrireductase inactive STAMP2 mutant,
which cannot increase intracellular ROS levels, did not affect ATF4
expression (Supplementary Fig S6E). These data show that oxidative
stress induced by STAMP2 is involved in increasing ATF4 expres-
sion in PCa cells.
STAMP2 depletes intracellular NADPH
We have recently shown that mouse Stamp2 is involved in NADPH
homeostasis in macrophages and regulates inflammatory responses
(ten Freyhaus et al, 2012). In addition, NADPH levels are inversely
correlated with ROS levels (Ying, 2008). We thus determined
whether STAMP2 regulates NADPH levels in PCa cells which may
be linked to its ability to increase ROS. Ectopic expression of
STAMP2 in LNCaP cells (Fig 9A) led to robust increases in iron
reductase activity and superoxide production (Fig 9B and C). In
addition, STAMP2 knockdown decreased ROS production in PCa
cells (Fig 9D, Supplementary Fig S7). Furthermore, expression of
wild-type STAMP2, but not an iron reductase-deficient STAMP2
mutant, resulted in a significant decrease in the NADPH/NADP+
ratio (Fig 9E). Consistently, STAMP2 knockdown in LNCaP cells
(Fig 9F), as well as the flavoenzyme inhibitor DPI (Fig 9G), also
significantly increased the NADPH/NADP+ ratio. These data suggest
that STAMP2 iron reductase activity is required for modulation of
the intracellular redox state and ROS levels.
Therapeutic targeting of STAMP2 by nanoliposomal siRNA
reverses PCa growth in vivo
The data presented above showed that STAMP2 promotes prolif-
eration, colony formation, anchorage-independent growth,
survival, and tumor growth of PCa cells. However, the role of
STAMP2 in tumorigenesis and the therapeutic potential of its
knockdown, if any, are not known. To assess this possibility,
STAMP2 was silenced using systemically administered nanoliposo-
mal siRNA in nude mice carrying xenografted tumors of LNCaP
or VCaP cells. This strategy has successfully been used in similar
experiments in various cancer models, including PCa (e.g. Landen
et al, 2005; Nick et al, 2011; Jin et al, 2013). As shown in
Fig 10A and B, whereas tumors continued to grow rapidly in
mice injected with the empty or control siRNA-loaded nanolipo-
somes, there was a dramatic and time-dependent reversal of
tumor size upon injection of nanoliposomes containing STAMP2
siRNA in both tumor models reaching regression of > 95% within
5 weeks. The in vivo knockdown efficacy was confirmed by qPCR
analysis in tumor tissues collected at the end of the experiments
(Supplementary Fig S8). These data establish that targeting
STAMP2 can profoundly reverse tumor growth in preclinical
models of human PCa.
Discussion
Here, we have demonstrated that STAMP2 promotes PCa tumori-
genesis and progression by serving as a proliferation and survival
factor and thus may serve as a potential therapeutic target. Our data
also reveal a novel mechanism through which androgen signaling
increases ROS levels in PCa cells through induction of STAMP2
expression and its oxidoreductase activity.
One of the factors that has been implicated in PCa is oxidative
stress (for a review, see Paschos et al, 2013). Several lines of
evidence have documented an altered prooxidant–antioxidant status
in PCa. For example, early studies found that androgen signaling
induced a shift toward a prooxidant state in PCa cells (Ripple et al,
1997; Sun et al, 2001). Consistently, it was shown that androgen
ablation reduced oxidative stress through down-regulation of NADPH
oxidase expression (Tam et al, 2003). Furthermore, increased ROS
and DNA damage have been documented in PCa (Frohlich et al,
2008). In keeping with these findings, somatic mutations that inacti-
vate the glutathione S-transferase P1 (GSTP1) gene have been identi-
fied in the majority of PCa cases (Nelson et al, 2004). Despite these
data, our knowledge has been limited on the molecular mechanisms
that regulate ROS levels in PCa cells. The results presented herein,
demonstrating the direct involvement of STAMP2 in ROS production
in PCa cells, provide new insight into these events.
The ability of STAMP2 to increase ROS levels is likely via
increasing ferrous iron levels in the cells which is then used as a
redox intermediate (the electron donor) for free radical production
(Okada, 1996). In addition, NADPH, which normally inhibits ROS
(Ying, 2008), is used up during the ferrous iron production by
STAMP2, thus further increasing ROS levels. It is also possible that
STAMP2 helps increase ROS levels in the cell through suppression
of the antioxidant defense system.
It was previously shown that the activation of the monoamine
oxidase system through the enzyme spermidine/spermine N1-
acetyltransferase (SSAT) may increase ROS levels in PCa cells (Basu
et al, 2009; Mehraein-Ghomi et al, 2010). Inhibition of monoamine
oxidases, even at levels that are tenfold higher than that required to
inhibit SSAT, did not affect STAMP2-induced ROS production in
LNCaP cells (data not shown) indicating that STAMP2- and SSAT-
mediated oxidative stress pathways in PCa cells are independent.
To elucidate the molecular mechanisms responsible for the
proliferative effect of STAMP2, we used gene expression profiling.
We found that ATF4 is one of the genes whose expression was most
significantly reduced upon STAMP2 knockdown. ATF4 is induced
by various cellular stresses, including metabolic, oxidative, and ER
stress, and is an important regulator of gene expression that is
involved in amino acid metabolism and transport, antistress
response (such as restoration of normal ER function and redox
balance), and cell survival (Harding et al, 2003; Ye & Koumenis,
2009). Elevated expression of ATF4 in cancer cells has been associ-
ated with resistance to some chemotherapeutic drugs, such as DNA-
damaging agents and proteasome inhibitors (Rzymski et al, 2009).
A recent study revealed that the GCN2-PERK-eIF2a-ATF4 pathway
is required for survival and proliferation of cancer cells in response
to nutrient deprivation (Ye et al, 2010). A recent study suggested
that L-type amino acid transporters, which are target genes of ATF4,
promote PCa cell survival through maintaining amino acid supple-
mentation (Wang et al, 2013); however, the exact role of ATF4 in
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PCa cells has not been determined to date. Here, we found that simi-
lar to depletion of STAMP2, ATF4 knockdown inhibited PCa cell
growth (Fig 7B and C). Furthermore, ectopic expression of ATF4
partially reversed growth inhibition that is induced by STAMP2
knockdown (Fig 7E and F). These data suggest that ATF4 directly
contributes to the proliferative activities of STAMP2 in PCa cells.
Consistent with the in vitro and in vivo data, STAMP2 expression
was significantly increased in human PCa compared with normal
prostate (Fig 1). In addition, STAMP2 levels correlated with tumor
grade and neoadjuvant hormone therapy response (Fig 4). A limita-
tion of these data is that almost all patients in these cohorts were
Caucasian, and thus, additional studies will be required to assess
whether our findings can be extended to all men with PCa. Further-
more, analysis of independent cohorts and even larger number of
patients is desirable.
Based on the data presented herein, we suggest the following
model as to how STAMP2 influences PCa growth (Fig 10C):
Androgens activate the AR that increases STAMP2 expression.
Through its iron reductase activity, STAMP2 reduces Fe3+ to
Fe2+ and at the same time consumes available NADPH. Both
increased Fe2+ and decreased NADPH then increase intracellular
ROS levels. ROS in turn activate the pathway that increases ATF4
expression which then activates expression of downstream targets
that are involved in PCa growth and progression. Other pathways
may also be involved in the prosurvival function of STAMP2 in
PCa cells, and further exploration is required.
In addition to STAMP2 effects on PCa growth and survival, and
its correlation with tumor grade and response to hormone therapy
(Figs 1 and 4), STAMP2 targeting by systemic administration of
nanoliposome-encapsulated siRNA resulted in profound tumor
regression in two independent preclinical models of human PCa
(Fig 10A and B). These findings suggest that STAMP2 could have
utility in the clinic as a biomarker, as well as a therapeutic target,
including in advanced disease.
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Figure 10. Targeting STAMP2 in preclinical models of PCa results in tumor regression.
A LNCaP cells were implanted subcutaneously into nu/nu mice. Once tumors reached 5 mm in size, mice (n = 5 per group) were given nanoliposome-encapsulated
control siRNA or STAMP2 siRNA as described in Materials and Methods. Tumor volumes were measured at the indicated time points. *P = 0.001.
B Same experiment as in (A), but VCaP cells were used instead. *P = 0.001.
C A model for STAMP2 effects on growth and survival of PCa cells. Once activated, AR increases STAMP2 expression. STAMP2 catalyzes reduction of Fe3+ to Fe2+, also
depleting NADPH levels, which increases ROS. Increased ROS then activate ATF4 expression which in turn activates target genes that adapt PCa cells to oxidative
stress resulting in cell proliferation and survival.
Data information: Student’s t-test was used to analyze the statistical significance between mice (n = 5 per group) treated with control siRNA vs STAMP2 siRNA. Error
bars indicate SEM.
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Materials and Methods
Cell culture
293T cells were obtained from the American Type Culture Collection
(LGC Standards) and routinely maintained in standard growth
conditions. LNCaP cells and VCaP cells (ATCC, LGC standard) were
routinely maintained in RPMI 1640 culture medium supplemented
with 10% fetal bovine serum (FBS), 5 mg/ml penicillin/streptomycin,
and 2 mM L-glutamine (Invitrogen) at 37°C in a humidified atmo-
sphere with 5% CO2. All the cell cultures were performed under
these conditions unless specifically indicated. Their response, or
lack thereof, to androgen treatment for growth, as well as in
reporter assays, was determined as a way to authenticate the PCa
lines. All cell lines were free of mycoplasma contamination.
Immunohistochemistry
This study was approved by the Regional Ethics Committee, REK
Sør-Øst (S-07443a), and material from still living patients was
included after their written consent. The prostate tissue microarrays
(TMAs) for Fig 1 were previously described (Klokk et al, 2007;
Wang et al, 2010). After deparaffinization, antigen retrieval was
done by autoclaving at 121°C for 10 min in 10 mM citrate buffer
(pH 6.4). The affinity purified STAMP2 antibody (Proteintech
Group, Inc.) was used at a dilution of 1:50 for 1 h at room tempera-
ture. The Supersensitive Detection kit (Biogenex) was used for anti-
gen detection (Klokk et al, 2007).
For the neoadjuvant hormone therapy (NHT) and PSA recurrent
samples, total of 194 prostate cancer specimens were obtained from
Vancouver Prostate Centre Tissue Bank. The H&E slides were
reviewed, and the desired areas were used to construct TMAs
(Beecher Instruments, MD, USA). All specimens were from radical
prostatectomies except 12 CRPC samples that were obtained
through transurethral resection of prostate (TURP). Details of the
material are presented in Supplementary Table S1. IHC was
conducted by Ventana autostainer model Discover XT (Ventana
Medical System, Tuscan, Arizona) with enzyme labeled biotin
streptavidin system and solvent-resistant DAB Map kit.
Scoring and statistical analysis of TMAs
For scoring, values on a four-point scale were assigned to each
immunostain. Descriptively, one represents no apparent staining or
very weak level of staining, two represents a faint or focal, question-
ably present stain, three represents a stain of convincing intensity in
a minority of cells, and four represents a stain of convincing inten-
sity in a majority of cells. SPSS 10.0 software was used for IHC
statistical analysis. To compare STAMP2 expression between benign
tissue and malignant tissue, Mann–Whitney U-test was applied. The
Kruskal–Wallis test was used for the analysis of correlation between
STAMP2 expression and tumor grade.
Correlation analysis of ATF4 and STAMP2 expression in
PCa samples
A PCa gene expression profile dataset available at the cBioCancer
Genomics Portal (GSE21032) (Taylor et al, 2010) was used for this
analysis. The samples (n = 150) were aligned by the expression level
of STAMP2. The subgroups showing the highest (n = 30) and the
lowest (n = 30) STAMP2 expression were then used for possible
correlation with the expression of ATF4 and two ATF4 target genes,
ASNS and SLC7A11. The results are displayed in a heat map generated
by the GSEA program. The statistical significance was determined by
t-test. The correlation test was further applied to PCa samples of other
two datasets, GSE35988 (n = 59) (Grasso et al, 2012) and GES6919
(n = 62) (Yu et al, 2004), using the same methodology.
Plasmids
Human STEAP, STAMP1, STAMP2, and STAMP3 cDNAs were
cloned into SR-alpha vector (kind gift from Tiliang Deng) to intro-
duce an N-terminal HA tag. STAMP2 cDNA was also cloned into
pcDNA4/HisMax-TOPO vector (Invitrogen). STAMP2 mutants were
generated from pcDNA4-HisMax-STAMP2 with GeneTailorTM Site-
Directed Mutagenesis System (Invitrogen). Inducible lentiviral
vector for overexpressing STAMP2 was generated from pGIPZ or
pTRIPZ vectors (Open Biosystems, Thermo Fisher Scientific, Inc.)
by removing shRNA coding fragment and replacing the GFP ORF
(pGIPZ) or RFP ORF (pTRIPZ) with the STAMP2 ORF. Precision
lentiORF ATF4 and Precision lentiORF RFP vectors were obtained
from Open Biosystems, Thermo Fisher Scientific, Inc. Inducible
adenoviral vector for overexpressing STAMP2 was generated as
described previously (Klokk et al, 2007).
Ectopic expression of STAMP2
To obtain cells stably expressing STAMP2, lentivirus-based vectors
were generated as described above and virus was produced with
Trans-LentiviralTM Packaging kit (Thermo Fisher Scientific). LNCaP
cells or 293T cells were transduced with lentivirus and selected with
puromycin.
NADPH measurements
Measurement of NADPH and NADP+ was performed using a previ-
ously described enzymatic cycling method (Ros et al, 2012). Briefly,
cells from a 6-cm dish were lysed in 400 ll of extraction buffer
(20 mM nicotinamide, 20 mM NaHCO3, 100 mM Na2CO3) and centri-
fuged. Twenty microliter of the supernatant of each sample was
loaded to a 96-well plate for determining total NADP level. To deter-
mine NADPH level, 150 ll of the supernatant was incubated at 60°C
for 30 min to decompose NADP+, and 20 ll of the sample was loaded
to 96-well plate. Then, 160 ll of NADP-cycling buffer (100 mM Tris–
HCl pH 8.0, 0.5 mM thiazolyl blue, 2 mM phenazine ethosulfate,
5 mM EDTA) containing 1.3 U of G6PD was added to the 96-well plate
containing 20 ll of the samples. After a 1-min incubation in the dark
at 30°C, 20 ll of 10 mM glucose 6-phosphate (G6P) was added to the
mixture, and the change in absorbance at 570 nm was measured every
30 s for 4 min at 30°C with a microplate reader. The concentration of
NADP+was calculated by subtracting [NADPH] from [total NADP].
Cell proliferation assay
Cells were cultured for the indicated times, trypsinized, stained with
trypan blue, and counted using a hemocytometer. The experiments
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were repeated at least three times with consistent results. Alterna-
tively, cell proliferation was determined by the use of Cell Counting
kit-8 from Sigma-Aldrich.
Colony formation assay
Cells were trypsinized, seeded on dishes, and cultured for 14 days.
The cells were then fixed and stained with 0.1% crystal violet, and
the total area covered by the colonies was measured.
Soft agar assay
Low-melting (LE) agarose was purchased from LONZA. Two
milliliter of 0.6% LE agarose (in culture medium) was layered in the
bottom of 6-cm dishes. A total of 5,000 cells suspended in 2 ml of
0.35% LE agarose (in culture medium) at 37°C were then plated on
top of the first layer. The cells in the top layer were fed with 100 ll
culture medium every 3 days. After 14 days, the cells were stained
with 0.005% crystal violet (in PBS) and then photographed. The
number of colonies (> 30 pixels) on each plate was counted using
an imaging system (Syngene).
Cell cycle analysis
Cells were synchronized at the G0/G1 phase by serum starvation for
48 h and then released into cell cycle by re-addition of 10% FBS.
After 24 h, cells were trypsinized, washed with PBS, and then fixed
in 70% ice-cold ethanol for 2 h at 4°C. To assess the cell cycle
profile, fixed cells were treated with RNase (Sigma-Aldrich), stained
with propidium iodide (PI) (Sigma-Aldrich), and analyzed by flow
cytometry using the CellQuest software.
Apoptosis assays
To detect pro-apoptotic factor-induced apoptosis, cells were treated
with either 50 ng/ml tumor necrosis factor (TNF)-related apoptosis-
inducing ligand (TRAIL; Enzo Life Sciences) or 20 lM LY294002
(Invitrogen) for 24 h or both agents for 6 h. Extent of apoptosis was
then detected by terminal deoxynucleotidyl transferase-mediated
dUTP nick-end labeling (TUNEL) and flow cytometry as described
by the manufacturer’s instructions (Roche).
Quantitative PCR
RNA extraction, cDNA synthesis, and quantitative PCR were
performed as described previously (Klokk et al, 2007). PCR primer
sequences are available upon request. A standard curve made
from serial dilutions of cDNA was used to calculate the relative
amount of the different cDNAs in each sample. The values were
normalized to the relative amount of the internal standard GAPDH
or TBP. The experiments were performed in triplicate with consis-
tent results.
Western blot analysis
Fractionation of subcellular proteins was done by using Subcellu-
lar Protein Fractionation Kit for cells (Thermo Fisher Scientific
Inc.). Western blot analysis was performed by standard methods.
Results shown are representative of at least two independent
experiments. Antibodies specific for cleaved caspase-3 (#9664),
cleaved PARP (#5625), and p21CIP1 (#2947) were from Cell
Signaling; antibody for STAMP2 (11944-1-AP) and ATF4 (10835-1-
AP) was from Proteintech Group Inc.; and antibodies for PCNA
(P8825) and GAPDH (G8795) were from Sigma. Antibody for
STAMP1 was described previously (Wang et al, 2010). All anti-
bodies were used at a dilution of 1:1,000, except for GAPDH
(1:5,000).
Small interfering RNA-mediated knockdown
LNCaP cells were transfected with ATF4 siRNA (Thermo Scientific
Dharmacon) or the other siRNAs (Qiagen) using Oligofectamine
(Invitrogen) according to the manufacturer’s recommendations. The
sequences of STAMP2 siRNAs are 50-AAUGCAGAGUACCUUGCU
CAU-30 and 50-UAUCCAUCACUCUUUGCUUGG-30. The SMARTpool
siRNA from (DharmaconGE) was used to knock down ATF4 or
ASNS.
Short hairpin RNA-mediated knockdown
Lentiviral pLKO.1 short hairpin RNA (shRNA) vectors targeting
human STAMP2 and non-silencing control vector were purchased
from Open Biosystems (Thermo Fisher Scientific, Inc.). Lentivirus
particles were produced in 293T cells according to the manufac-
turer’s instructions. LNCaP cells were transduced with the lentiviral
particles following puromycin selection (1 lg/ml) for 10 days. The
cells stably expressing shRNA were pooled and maintained in
medium containing puromycin (0.2 lg/ml).
Ferrireductase activity assay
Ferrireductase assays were conducted as previously described (Oh-
gami et al, 2005, 2006). Briefly, cells were cultured in 12-well plates
to 80–90% confluence. After three washes with phosphate-buffered
saline (PBS, pH 7.2), the cells were incubated in dark in iron uptake
buffer (IUB: 25 mM MES, 25 mM MOPS, 140 mM NaCl, 5 mM
glucose, 5.4 mM KCl, 1.8 mM CaCl2, 800 lM MgCl2) containing
50 lM ferric nitrilotriacetate (Fe3+-NTA) and 200 lM ferrozine for
30–60 min. The production of ferrous iron was determined by moni-
toring the increase in absorbance at k = 562 nm using a spectropho-
tometer. The experiments were repeated at least three times with
consistent results.
Intracellular ROS assays
Nitro blue tetrazolium (NBT) staining: NBT staining was carried
out as described previously (Serrander et al, 2007). The amount
of reduced NBT was quantified by spectrophotometry. The
experiments were repeated at least three times with consistent
results.
CellROX staining: Cells were stained with 500 nM CellROX Green
reagent (Life Technologies) for 30 min and then trypsinized. Intra-
cellular fluorescence intensity was measured using the FL1 channel
in a BD FACSCalibur flow cytometer. Data were analyzed using Cell-
Quest software. The experiments were repeated at least three times
with consistent results.
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Xenograft experiments in SCID or nude mice
For injection into mice, 3 million LN-shST2 or LN-Scr cells were
suspended in 50 ll RPMI 1640 and mixed with 50 ll Matrigel
(BD Biosciences). The mixtures were then subcutaneously
implanted in random into NOD/SCID IL2R gamma null mice in
both hind flanks. Tumor size was measured weekly in two dimen-
sions with calipers, and the tumor volume V was calculated
according to the formula: V = W2 × L × 0.5, where W and L are
tumor width and length, respectively. No blinding was carried out.
Same procedure was conducted in nude mice (BALBC Nu/Nu,
5 weeks of age) for 22Rv1 cells stably expressing shRNA control
or shRNA targeting STAMP2. All procedures on animals, including
mouse strain, animal sex, age, number of animals allowed to use,
and housing details, were approved by the National Animal
Research Authority and were conducted according to the regula-
tions of the Federation of European Laboratory Animals Science
Association.
Nanoliposomal siRNA targeting in PCa xenografts
In vivo therapeutic targeting of STAMP2 by systemically adminis-
tered nanoliposomal siRNA was carried out as described previously
(Landen et al, 2005; Nick et al, 2011; Shao et al, 2012; Stone et al,
2012). Athymic male nu/nu mice (5 weeks old) were used in
random to inject LNCaP or VCaP cells (2 × 106) subcutaneously into
the right flank of each mouse (six mice per group) with 10% matri-
gel. Once tumors reached 3–5 mm in size, mice were given nano-
liposome-encapsulated non-silencing control siRNA or STAMP2
siRNA 150 lg/kg (~4 lg siRNA/mouse), twice a week from the tail
vein in 100 ll saline. At the indicated time points, the tumor
volumes were measured weekly in two dimensions with calipers
and the tumor volume V was calculated according to the formula:
V = W2 × L × 0.5, where W and L are tumor width and length,
respectively. No blinding was carried out. After 5 weeks of nano-
liposomal siRNA treatment, tumors were harvested.
Statistical analysis
Mean and standard deviation values were calculated using Microsoft
Excel software. The treatment effects in each experiment were
compared by two-sided t-test. One-way analysis of variance (ANOVA)
with a post hoc test was used for comparing multiple independent
variables. Differences between groups were considered significant at
P < 0.05. All experiments were repeated three times. In animal
experiments, we used 5–6 animals per group. For all in vitro experi-
ments, the results of one representative experiment are shown as
mean values  SD or  SEM as indicated in the respective figure
legends.
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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